The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Hot topic: Geriatric Assessment in Hematology (GAH) scale
As age increases, the chance of a patient with hematological malignancies having further complications increases. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Raúl Córdoba, MD, PhD, MS, of the Fundación Jiménez Diaz University Hospital, Madrid, Spain, introduces the Geriatric Assessment in Hematology (GAH) scale: a tool used to identify elderly patients with multiple myeloma, chronic lymphocytic leukemia or high-risk myelodysplastic syndromes that are fit and can be treated similarly to young patients.
